Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) and Shingrix (zoster ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.

GlaxoSmithKline, the maker of the shingles vaccine Shingrix that has been in short supply, told customers Jan. 10 that more shipments of the vaccine are on the way to U.S. pharmacies, according to ...

GSK PLC GSK 1.14% extended its collaboration with Chongqing Zhifei Biological Products 300122 1.89% to commercialize its shingles vaccine Shingrix in China until 2034. The British pharma company ...